Zimmer Biomet (ZBH) shares reached a session low on Tuesday as the company issued cautious remarks on its outlook during its presentation at the ongoing J.P. Morgan Healthcare Conference in San Francisco.
While the orthopedic device maker, which has lost more than 12% over the past 12 months, did not issue an outlook at the event, CEO Ivan Tornos said that his company expects to tone down investor expectations ahead of its earnings release on February 10.
“We're not here to give guidance. We'll talk about guidance -- February 10, 2026,” Tornos said, adding, “But we're going to temper the enthusiasm.”
“I want to make sure that we provide guidance that aligns to the level of transformation that is going to take place in 2026,” he said, citing ZBH's U.S. and international operations.
Zimmer Biomet’s (ZBH) MedTech rivals, namely Boston Scientific (BSX), Globus Medical (GMED), Stryker Corporation (SYK), and Medtronic (MDT), are also in the red.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.